FIRMAGON IS A GNRH RECEPTOR ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER.
STARTING DOSE:
240 MG GIVEN AS TWO SUBCUTANEOUS INJECTIONS OF 120 MG AT A CONCENTRATION OF 40 MG/ML GIVEN IN ABDOMINAL REGION.
MAINTENANCE DOSE, ADMINISTERED EVERY 28 DAYS;
80 MG GIVEN AS ONE SUBCUTANEOUS INJECTION AT A CONCENTRATION OF 20 MG/ML